Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00088283 · ClinicalTrials.gov registry record · Phase 2
Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)
A Phase 2 study of Retinal Vein Occlusion, sponsored by Eyetech Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
- 20
- Study locations
NCT00088283: Completed Phase 2 study of Retinal Vein Occlusion, sponsored by Eyetech Pharmaceuticals.
NCT00088283 is a Phase 2 study of Retinal Vein Occlusion that has completed, run by Eyetech Pharmaceuticals. The registered enrollment target is 90 participants, below the 851-participant average among 11 other Retinal Vein Occlusion trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00088283, a Phase 2 study of Retinal Vein Occlusion, has completed, sponsored by Eyetech Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
- 20
- Study locations
Study Summary
Eyetech Pharmaceuticals Inc. and Pfizer, Inc. are studying an investigational drug, MacugenTM, for the possible treatment of CRVO. An investigational drug is one that has not been approved by the U.S. Food and Drug Administration (FDA). This investigational drug may slow the growth of abnormal blood vessels in the eye and may reduce tissue swelling in the eye. The purpose of this study is to compare the safety and efficacy of a Macugen™ injection to a "pretend" injection. In addition, the purpose of this study is to measure the action of the study drug in the body over a period of time and to check for the presence of the study drug in your blood (called pharmacokinetics or PK). This study will involve approximately 90 people. People who decide to participate will have an equal chance (1 in 3) to receive one of three study injections, two of which are Macugen™ and one of which is a "pretend" injection.
Conditions Studied
Interventions
- DRUG pegaptanib sodium
Study Locations (20)
Massachusetts
- New England Eye Center - Boston
- Massachusetts Eye & Ear Infirmary - Boston
- Lahey Clinic, The Eye Institute - Peabody
Arizona
- Retina Centers, P.C., Northwest Location - Tucson
- Retina Associates, SW - Tucson
California
- Jules Stein Institute - Los Angeles
- Orange County Retina Associates - Santa Ana
Florida
- Retina Group of Florida - Fort Lauderdale
- Bascom Palmer Eye Institute - Miami
Maryland
- Retina Group of Washington - Chevy Chase
- Cumberland Valley Retina Center - Hagerstown
Michigan
- Kresge Eye Institute - Detroit
- Associated Retinal Consultants - Royal Oak
Connecticut
- New England Retina Associates - Hamden
Illinois
- The University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2004-05 |
| Phase | Phase 2 |
What the finished NCT00088283 record still lists
NCT00088283 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 851-participant average among 11 other Retinal Vein Occlusion trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Retinal Vein Occlusion appearing as the primary indexed condition, and to 1 intervention - of which pegaptanib sodium is the first listed.
NCT00088283 names 20 study sites across 13 states, led by Massachusetts, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT00088283 about?
NCT00088283 is a clinical study titled "Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)". Eyetech Pharmaceuticals Inc. and Pfizer, Inc. are studying an investigational drug, MacugenTM, for the possible treatment of CRVO. An investigational drug is one that has not been approved by the U.S. Food and Drug Administration (FDA). This investigational drug may slow the growth of abnormal blood...
What is the current status of trial NCT00088283?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2004-05.
What conditions does trial NCT00088283 study?
This clinical trial studies the following conditions: Retinal Vein Occlusion.
What interventions are being tested in trial NCT00088283?
The interventions under investigation include: pegaptanib sodium (DRUG).
Who is sponsoring clinical trial NCT00088283?
This trial is sponsored by Eyetech Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00088283 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Retinal Vein Occlusion
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00088283's enrollment target sits among peer trials
90 7th of 11 higher than 5 of 11 other Retinal Vein Occlusion trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Retinal Vein Occlusion trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Retinal Vein Occlusion
COMPLETED · Phase 2
-
Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium
RECRUITING · Early Phase 1
-
National Eye Institute Biorepository for Retinal Diseases
RECRUITING
-
Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease
RECRUITING · NA
-
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
ACTIVE NOT RECRUITING
-
30g vs 33g Needle for Intravitreal Injections
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia